541 related articles for article (PubMed ID: 26121376)
1. Impact of immunosuppressive therapy on hepatitis B vaccination in inflammatory bowel diseases.
Belle A; Baumann C; Bigard MA; Zallot C; Gizard E; Guéant JL; Bronowicki JP; Peyrin-Biroulet L
Eur J Gastroenterol Hepatol; 2015 Aug; 27(8):877-81. PubMed ID: 26121376
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of hepatitis B vaccination and revaccination and factors impacting on response in patients with inflammatory bowel disease.
Gisbert JP; Villagrasa JR; Rodríguez-Nogueiras A; Chaparro M
Am J Gastroenterol; 2012 Oct; 107(10):1460-6. PubMed ID: 23034605
[TBL] [Abstract][Full Text] [Related]
3. Treatment with infliximab or azathioprine negatively impact the efficacy of hepatitis B vaccine in inflammatory bowel disease patients.
Andrade P; Santos-Antunes J; Rodrigues S; Lopes S; Macedo G
J Gastroenterol Hepatol; 2015 Nov; 30(11):1591-5. PubMed ID: 25967740
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the effectiveness of two protocols for vaccination (standard and double dosage) against hepatitis B virus in patients with inflammatory bowel disease.
Gisbert JP; Menchén L; García-Sánchez V; Marín I; Villagrasa JR; Chaparro M
Aliment Pharmacol Ther; 2012 Jun; 35(12):1379-85. PubMed ID: 22530631
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis B immunity and response to booster vaccination in children with inflammatory bowel disease treated with infliximab.
Moses J; Alkhouri N; Shannon A; Raig K; Lopez R; Danziger-Isakov L; Feldstein AE; Zein NN; Wyllie R; Carter-Kent C
Am J Gastroenterol; 2012 Jan; 107(1):133-8. PubMed ID: 21876562
[TBL] [Abstract][Full Text] [Related]
6. Impact of surveillance of hepatitis b and hepatitis c in patients with inflammatory bowel disease under anti-TNF therapies: multicenter prospective observational study (REPENTINA 3).
Loras C; Gisbert JP; Saro MC; Piqueras M; Sánchez-Montes C; Barrio J; Ordás I; Montserrat A; Ferreiro R; Zabana Y; Chaparro M; Fernández-Bañares F; Esteve M;
J Crohns Colitis; 2014 Nov; 8(11):1529-38. PubMed ID: 25052345
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity of hepatitis B vaccine in patients with inflammatory bowel disease and the benefits of revaccination.
Cossio-Gil Y; Martínez-Gómez X; Campins-Martí M; Rodrigo-Pendás JÁ; Borruel-Sainz N; Rodríguez-Frías F; Casellas-Jordà F
J Gastroenterol Hepatol; 2015 Jan; 30(1):92-8. PubMed ID: 25160690
[TBL] [Abstract][Full Text] [Related]
8. SEROCONVERSION ANALYSIS AFTER HABITUAL HEPATITIS B VACCINATION SCHEME IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES.
Cunha IS; Silva TCD; Malluta ÉF; Scolaro BL; Velho PS; Stall J
Arq Gastroenterol; 2020; 57(1):69-73. PubMed ID: 32294738
[TBL] [Abstract][Full Text] [Related]
9. Factors for hepatitis B vaccination and abnormal liver function in Chinese patients with inflammatory bowel disease: a single center experience.
Leung WK; Liu KSh; Seto WK; Chan KH; Tong T; Yuen MF; Lai CL; Hung IF
J Dig Dis; 2013 Nov; 14(11):596-603. PubMed ID: 23870196
[TBL] [Abstract][Full Text] [Related]
10. Sci-B-VacTM Vs ENGERIX-B Vaccines for Hepatitis B Virus in Patients with Inflammatory Bowel Diseases: A Randomised Controlled Trial.
Etzion O; Novack V; Perl Y; Abel O; Schwartz D; Munteanu D; Abufreha N; Ben-Yaakov G; Maoz ED; Moshaklo A; Dizingf V; Fich A
J Crohns Colitis; 2016 Aug; 10(8):905-12. PubMed ID: 26928962
[TBL] [Abstract][Full Text] [Related]
11. Fendrix vs Engerix-B for Primo-Vaccination Against Hepatitis B Infection in Patients With Inflammatory Bowel Disease: A Randomized Clinical Trial.
Chaparro M; Gordillo J; Domènech E; Esteve M; Barreiro-de Acosta M; Villoria A; Iglesias-Flores E; Blasi M; Naves JE; Benítez O; Nieto L; Calvet X; García-Sánchez V; Villagrasa JR; Marin AC; Donday MG; Abad-Santos F; Gisbert JP
Am J Gastroenterol; 2020 Nov; 115(11):1802-1811. PubMed ID: 33156099
[TBL] [Abstract][Full Text] [Related]
12. Antibody titration and immune response of Iranian beta-thalassemic patients to hepatitis B virus vaccine (booster effect).
Azarkeivan A; Karimi G; Shaiegan M; Maghsudlu M; Tabbaroki A
Pediatr Hematol Oncol; 2009 Jun; 26(4):195-201. PubMed ID: 19437322
[TBL] [Abstract][Full Text] [Related]
13. Immune response to hepatitis B vaccination among people with inflammatory bowel diseases: A systematic review and meta-analysis.
Jiang HY; Wang SY; Deng M; Li YC; Ling ZX; Shao L; Ruan B
Vaccine; 2017 May; 35(20):2633-2641. PubMed ID: 28404358
[TBL] [Abstract][Full Text] [Related]
14. Response to vaccination against hepatitis B virus with a schedule of four 40-μg doses in cirrhotic patients evaluated for liver transplantation: factors associated with a response.
Gutierrez Domingo I; Pascasio Acevedo JM; Alcalde Vargas A; Ramos Cuadra A; Ferrer Ríos MT; Sousa Martin JM; Sayago Mota M; Giráldez Gallego A; Suárez Artacho G
Transplant Proc; 2012; 44(6):1499-501. PubMed ID: 22841195
[TBL] [Abstract][Full Text] [Related]
15. Inadequate seroprotection against hepatitis B virus and one detected case of hepatitis C virus infection among patients with inflammatory bowel disease.
Waszczuk E; Waszczuk KM; Mulak A; Paradowski L
Eur J Gastroenterol Hepatol; 2016 Jun; 28(6):628-32. PubMed ID: 26904976
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of hepatitis-B viral markers in patients with inflammatory bowel disease in a hepatitis-B-endemic area: inadequate protective antibody levels in young patients.
Kim ES; Cho KB; Park KS; Jang BI; Kim KO; Jeon SW; Kim EY; Yang CH; Kim WJ;
J Clin Gastroenterol; 2014 Jul; 48(6):553-8. PubMed ID: 24162170
[TBL] [Abstract][Full Text] [Related]
17. Kinetics of anti-hepatitis B surface antigen titers after hepatitis B vaccination in patients with inflammatory bowel disease.
Gisbert JP; Villagrasa JR; Rodríguez-Nogueiras A; Chaparro M
Inflamm Bowel Dis; 2013 Mar; 19(3):554-8. PubMed ID: 23380936
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis B virus serologic markers and anti-hepatitis B vaccination in patients with diabetes.
Halota W; Muszyńska M; Pawłowska M
Med Sci Monit; 2002 Jul; 8(7):CR516-9. PubMed ID: 12118201
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of hepatitis B and C and risk factors for nonvaccination in inflammatory bowel disease patients in Northeast France.
Chevaux JB; Nani A; Oussalah A; Venard V; Bensenane M; Belle A; Gueant JL; Bigard MA; Bronowicki JP; Peyrin-Biroulet L
Inflamm Bowel Dis; 2010 Jun; 16(6):916-24. PubMed ID: 19885908
[TBL] [Abstract][Full Text] [Related]
20. Significance and anamnestic response in isolated hepatitis B core antibody-positive individuals 18 years after neonatal hepatitis B virus vaccination in Taiwan.
Su FH; Bai CH; Chu FY; Lin YS; Su CT; Yeh CC
Vaccine; 2012 Jun; 30(27):4034-9. PubMed ID: 22531558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
